IN2015KN00262A - - Google Patents

Info

Publication number: IN2015KN00262A
Authority: IN; India
Prior art keywords: forms; isoquinoline; phenoxy; carbonyl; hydroxy
Prior art date: 2012-07-16

Application number

Other languages

English (en)

Inventor

Claudia Witschi

Jung Min Park

Michael D Thompson

Michael John Martinelli

David A Yeowell

Michael P Arend

Original Assignee

Fibrogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-16

Filing date

2013-07-15

Publication date

2015-06-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015KN00262(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-15 Application filed by Fibrogen Inc filed Critical Fibrogen Inc

2015-06-12 Publication of IN2015KN00262A publication Critical patent/IN2015KN00262A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Toxicology (AREA)

IN262KON2015 2012-07-16 2013-07-15 IN2015KN00262A (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261672191P	2012-07-16	2012-07-16
US201361768297P	2013-02-22	2013-02-22
US201361832566P	2013-06-07	2013-06-07
PCT/US2013/050539 WO2014014835A2 (en)	2012-07-16	2013-07-15	Crystalline forms of a prolyl hydroxylase inhibitor

Publications (1)

Publication Number	Publication Date
IN2015KN00262A true IN2015KN00262A (pt)	2015-06-12

Family

ID=48857025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN262KON2015 IN2015KN00262A (pt)	2012-07-16	2013-07-15

Country Status (29)

Country	Link
US (5)	US9115085B2 (pt)
EP (3)	EP4029854A1 (pt)
JP (2)	JP6491093B2 (pt)
KR (4)	KR102149380B1 (pt)
CN (9)	CN109369524A (pt)
AU (1)	AU2013290438C1 (pt)
BR (1)	BR112015001101A2 (pt)
CA (1)	CA2879242C (pt)
CY (2)	CY1120805T1 (pt)
DK (2)	DK2872488T3 (pt)
ES (2)	ES2689430T3 (pt)
FR (1)	FR22C1030I2 (pt)
HK (1)	HK1243409A1 (pt)
HR (2)	HRP20220182T1 (pt)
HU (2)	HUE041458T2 (pt)
IL (1)	IL236626B (pt)
IN (1)	IN2015KN00262A (pt)
LT (3)	LT2872488T (pt)
MX (1)	MX355428B (pt)
MY (1)	MY182428A (pt)
NO (1)	NO2022024I1 (pt)
NZ (1)	NZ704662A (pt)
PL (2)	PL2872488T3 (pt)
PT (2)	PT3470397T (pt)
RS (2)	RS63122B1 (pt)
SG (3)	SG10201700873UA (pt)
SI (2)	SI3470397T1 (pt)
SM (2)	SMT202200095T1 (pt)
WO (1)	WO2014014835A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0411055B1 (pt)	2003-06-06	2018-08-21	Fibrogen, Inc	Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
US8927591B2 (en)	2008-11-14	2015-01-06	Fibrogen, Inc.	Thiochromene derivatives as HIF hydroxylase inhibitors
EP2670750B1 (en)	2011-02-02	2016-09-14	Fibrogen, Inc.	Naphthyridine derivatives as inhibitors of hypoxia inducible factor
KR102149380B1 (ko) *	2012-07-16	2020-08-28	피브로겐, 인크.	프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
WO2014014834A1 (en)	2012-07-16	2014-01-23	Fibrogen, Inc.	Process for making isoquinoline compounds
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
SMT202000190T1 (it)	2013-06-06	2020-05-08	Fibrogen Inc	Formulazioni farmaceutiche di un inibitore di hif-idrossilasi
CN103694172A (zh) *	2013-12-26	2014-04-02	辽宁亿灵科创生物医药科技有限公司	含氮杂芳基化合物的衍生物
WO2016045125A1 (en)	2014-09-28	2016-03-31	Merck Sharp & Dohme Corp.	Inhibitors of hif prolyl hydroxylase
CN104892509B (zh) *	2015-06-04	2018-03-09	苏州明锐医药科技有限公司	诺得司他的制备方法
CN106916105A (zh) *	2015-12-28	2017-07-04	徐州万邦金桥制药有限公司	一种纯化可博美的方法
WO2017143131A1 (en) *	2016-02-19	2017-08-24	Cornell University	Hif-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106187888A (zh) *	2016-07-18	2016-12-07	江苏德源药业股份有限公司	Fg‑4592单晶及其制备方法
CN108017583B (zh) *	2016-11-01	2021-04-06	徐州万邦金桥制药有限公司	一种可博美的制备方法
CN107382986B (zh) *	2017-08-02	2022-09-20	江苏艾立康医药科技有限公司	4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
BR112020002939A2 (pt) *	2017-08-11	2020-08-04	Dr. Reddy¿S Laboratories Limited	polimorfos e cocristais de roxadustat
WO2019042485A1 (en)	2017-08-30	2019-03-07	Zentiva, K.S.	FORMS IN THE STRONG STATE OF ROXADUSTAT
US11192860B2 (en)	2017-09-04	2021-12-07	Sandoz Ag	Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
US11363815B2 (en)	2018-06-05	2022-06-21	Shenyang University Of Chemical Technology	Trifluoroethyl thioether (sulfoxide) substituted benzene compound and use thereof
CN111320583A (zh) *	2018-12-14	2020-06-23	广东东阳光药业有限公司	诺德司他新晶型及其制备方法
CN109369525A (zh) *	2018-12-29	2019-02-22	安礼特（上海）医药科技有限公司	罗沙司它的新晶型及其制备方法
WO2020217190A1 (en) *	2019-04-26	2020-10-29	Dr. Reddy’S Laboratories Limited	Process for the purification of roxadustat
CN112679428A (zh) *	2019-10-17	2021-04-20	罗欣药业(上海)有限公司	罗沙司他新晶型及其制备方法
JP2022553706A (ja) *	2019-10-22	2022-12-26	▲蘇▼州科睿思制▲葯▼有限公司	低酸素誘導因子－プロリルヒドロキシラーゼ阻害剤の結晶形
CN110721185B (zh) *	2019-11-13	2022-04-12	南京市儿童医院	罗沙司他用于心肌保护的用途
CN112961107B (zh) *	2019-12-13	2024-06-25	罗欣药业(上海)有限公司	罗沙司他的晶型及其制备方法
WO2021186356A1 (en) *	2020-03-17	2021-09-23	Cadila Healthcare Limited	Formulation comprising hif prolyl hydroxylase inhibitors
CN111205224B (zh) *	2020-04-22	2020-08-25	南京佰麦生物技术有限公司	一种罗沙司他水合物的晶型及其制备方法和应用
CN113754569B (zh) *	2020-06-04	2024-07-02	四川国为制药有限公司	一种中间体化合物及其制备方法和用途
CN111533691A (zh) *	2020-06-08	2020-08-14	重庆三圣实业股份有限公司	一种罗沙司他的制备方法
CN114057643B (zh) *	2020-08-04	2023-02-28	成都苑东生物制药股份有限公司	一种罗沙司他共晶及其制备方法
CN112194624A (zh) *	2020-11-18	2021-01-08	江苏豪森药业集团有限公司	一种异喹啉类化合物的晶型及其制备方法
CN112500344B (zh) *	2020-11-18	2022-07-01	江苏豪森药业集团有限公司	罗沙司他晶型及其制备方法
CN115724796A (zh) *	2021-08-26	2023-03-03	成都苑东生物制药股份有限公司	一种罗沙司他新晶型及其制备方法
CN113956200A (zh) *	2021-12-16	2022-01-21	南京威凯尔生物医药科技有限公司	一种粒径控制的罗沙司他原料药的结晶工艺

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4036964A (en)	1973-10-11	1977-07-19	Beecham Group Limited	Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en)	1973-10-30	1976-11-02	Sandoz, Inc.	3-Substituted-4-aryl isoquinolines
DE2818423A1 (de)	1978-04-27	1979-11-08	Hoechst Ag	Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de)	1982-09-09	1984-03-15	Hoechst Ag, 6230 Frankfurt	Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en)	1983-02-04	1985-12-10	Kirin-Amgen, Inc.	A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en)	1983-05-19	1985-12-17	Hoffmann-La Roche Inc.	Substituted isoquinolines
US4584379A (en)	1985-01-22	1986-04-22	Merrell Dow Pharmaceuticals Inc.	Isoquinoline thromboxane synthetase inhibitors
US4667016A (en)	1985-06-20	1987-05-19	Kirin-Amgen, Inc.	Erythropoietin purification
US4822800A (en)	1986-06-09	1989-04-18	Ortho Pharmaceutical Corporation	Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en)	1987-11-27	1990-10-30	Hoechst-Roussel Pharmaceuticals Inc.	1-aryl-3-isoquinolinecarboxamides
US4952588A (en)	1987-11-27	1990-08-28	Hoechst-Roussel Pharmaceuticals Inc.	1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
DK0650960T3 (da)	1993-11-02	1997-09-01	Hoechst Ag	Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
EP0650961B1 (de)	1993-11-02	1997-03-05	Hoechst Aktiengesellschaft	Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en)	1993-12-30	1995-07-01	Klaus Weidmann	Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
WO1996018616A1 (en)	1994-12-12	1996-06-20	Merck & Co., Inc.	Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en)	1995-09-28	2002-12-01	Hoechst Ag	Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
CA2272565A1 (en)	1996-11-27	1998-06-04	Du Pont Pharmaceuticals Company	Integrin receptor antagonists
DE19746287A1 (de)	1997-10-20	1999-04-22	Hoechst Marion Roussel De Gmbh	Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr)	1998-06-22	1999-12-24	Centre Nat Rech Scient	Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it)	1998-10-15	2000-09-29	Zambon Spa	Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en)	1999-04-26	2000-11-02	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1315220B1 (it) *	1999-12-13	2003-02-03	Ipm Ind Plastica Monregalese	Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
IT1320162B1 (it)	2000-02-09	2003-11-18	Rotta Research Lab	Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi)	2000-09-15	2000-09-15	Orion Yhtymae Oyj	Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en)	2001-03-20	2005-02-15	Dana Farber Cancer Institute, Inc.	Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en)	2001-03-21	2004-07-29	Maxwell Patrick Henry	Assays, methods and means
AU2002312371A1 (en)	2001-06-13	2002-12-23	Roland W. Burli	Aryl-benzimidazole compounds having antiinfective activity
EP1401817A4 (en)	2001-06-13	2005-11-02	Genesoft Pharmaceuticals Inc	ISOQUINOLINE COMPOUNDS WITH ANTI-INFECTIOUS ACTIVITY
US6762318B2 (en)	2001-12-03	2004-07-13	Novo Nordisk A/S	Glucagon antagonists
CN100522946C (zh)	2001-12-06	2009-08-05	法布罗根股份有限公司	低氧诱导因子(HIF)α的稳定化
US8318703B2 (en)	2001-12-06	2012-11-27	Fibrogen, Inc.	Methods for improving kidney function
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
US7618940B2 (en)	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
ME00076B (me)	2002-12-16	2011-02-10	Kissei Pharmaceutical	Lijek u čvrstom obliku za oralnu primjenu
WO2005007192A2 (en)	2003-06-06	2005-01-27	Fibrogen, Inc.	Cytoprotection through the use of hif hydroxylase inhibitors
BRPI0411055B1 (pt)	2003-06-06	2018-08-21	Fibrogen, Inc	Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase
US8614204B2 (en)	2003-06-06	2013-12-24	Fibrogen, Inc.	Enhanced erythropoiesis and iron metabolism
WO2005009962A1 (en)	2003-07-15	2005-02-03	Merck & Co., Inc.	Hydroxypyridine cgrp receptor antagonists
WO2005011696A1 (en)	2003-08-01	2005-02-10	Fibrogen, Inc.	Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
JP2007501844A (ja)	2003-08-08	2007-02-01	トランス　テック　ファーマ，インコーポレイテッド	アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
CN1929847B (zh)	2004-03-16	2011-01-19	旭化成制药株式会社	含有法舒地尔的制剂及改善其稳定性的方法
ATE443775T1 (de)	2004-05-28	2009-10-15	Fibrogen Inc	Hif-prolylhydroxylase-aktivitätstest
GB2421013B (en)	2004-12-10	2007-07-11	Amcor Flexibles Europe As	Packaging with an openable top wall
JP4792048B2 (ja)	2005-03-02	2011-10-12	ファイブロゲンインコーポレイティッド	チエノピリジン化合物およびその使用方法
WO2006133391A2 (en)	2005-06-06	2006-12-14	Fibrogen, Inc.	Improved treatment for anemia using a hif-alpha stabilising agent
US8530404B2 (en) *	2005-06-15	2013-09-10	Fibrogen, Inc.	Compounds and methods for treatment of cancer
UA97349C2 (uk)	2005-09-08	2012-02-10	Х. Луннбэк А/С	Стійкі тверді склади сертиндолу
JP5161793B2 (ja)	2006-01-27	2013-03-13	フィブロジェン，インコーポレイテッド	低酸素症誘導因子（ｈｉｆ）を安定化するシアノイソキノリン化合物
CN101420980A (zh)	2006-02-16	2009-04-29	菲布罗根公司	治疗中风的化合物和方法
CN101460497A (zh)	2006-04-04	2009-06-17	菲布罗根有限公司	作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007141743A2 (en)	2006-06-06	2007-12-13	Ranbaxy Laboratories Limited	A tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en)	2006-06-15	2010-05-11	Fibrogen, Inc.	Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en)	2006-06-15	2007-12-20	Fibrogen, Inc.	Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja)	2007-04-27	2015-03-11	ニプロ株式会社	経口固形製剤及びその製造方法
CA2701385A1 (en)	2007-10-12	2009-04-16	Astrazeneca Ab	Composition 064
EP2227475B1 (en)	2007-12-03	2014-02-19	Fibrogen, Inc.	Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009089547A1 (en)	2008-01-11	2009-07-16	Fibrogen, Inc.	Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en)	2008-02-05	2012-12-04	Fibrogen, Inc.	Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en)	2008-08-20	2012-07-10	Fibrogen, Inc.	Compounds and methods for their use
US8927591B2 (en)	2008-11-14	2015-01-06	Fibrogen, Inc.	Thiochromene derivatives as HIF hydroxylase inhibitors
JP5479949B2 (ja)	2009-04-08	2014-04-23	株式会社東芝	測定装置、測定方法、及び二酸化炭素回収システム
JP2010248106A (ja)	2009-04-14	2010-11-04	Dainippon Sumitomo Pharma Co Ltd	フィルムコーティング錠
JP2012176899A (ja)	2009-05-19	2012-09-13	Mitsubishi Tanabe Pharma Corp	２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US8339523B2 (en)	2010-05-18	2012-12-25	Kabushiki Kaisha Toshiba	Television apparatus and electronic apparatus
CN101880914B (zh)	2010-05-25	2012-09-12	中国科学院微电子研究所	利用等离子体浸没离子注入制备黑硅的方法
US20140171465A1 (en)	2011-01-13	2014-06-19	Fibrogen, Inc.	Methods For Increasing Reticulocyte Hemoglobin Content
EP2670750B1 (en)	2011-02-02	2016-09-14	Fibrogen, Inc.	Naphthyridine derivatives as inhibitors of hypoxia inducible factor
JP6099644B2 (ja) *	2011-07-22	2017-03-22	ベイジンベータファーマシューティカルズカンパニー，リミテッド	プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
WO2013070908A1 (en)	2011-11-09	2013-05-16	Fibrogen, Inc.	Therapeutic method
JP6129217B2 (ja)	2012-03-09	2017-05-17	フィブロジェンインコーポレイテッド	Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物
KR102149380B1 (ko)	2012-07-16	2020-08-28	피브로겐, 인크.	프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
WO2014014834A1 (en)	2012-07-16	2014-01-23	Fibrogen, Inc.	Process for making isoquinoline compounds
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
RU2666144C2 (ru)	2013-01-24	2018-09-06	Фиброген, Инк.	Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
SMT202000190T1 (it)	2013-06-06	2020-05-08	Fibrogen Inc	Formulazioni farmaceutiche di un inibitore di hif-idrossilasi

2013
- 2013-07-15 KR KR1020157003613A patent/KR102149380B1/ko active Active
- 2013-07-15 CN CN201810750543.3A patent/CN109369524A/zh active Pending
- 2013-07-15 CN CN201310302481.7A patent/CN103539735B/zh active Active
- 2013-07-15 HU HUE13740185A patent/HUE041458T2/hu unknown
- 2013-07-15 JP JP2015523160A patent/JP6491093B2/ja active Active
- 2013-07-15 CN CN201710546354.XA patent/CN107382859B/zh active Active
- 2013-07-15 PL PL13740185T patent/PL2872488T3/pl unknown
- 2013-07-15 SM SM20220095T patent/SMT202200095T1/it unknown
- 2013-07-15 KR KR1020227041256A patent/KR20220164068A/ko not_active Ceased
- 2013-07-15 AU AU2013290438A patent/AU2013290438C1/en active Active
- 2013-07-15 BR BR112015001101A patent/BR112015001101A2/pt not_active Application Discontinuation
- 2013-07-15 SI SI201331973T patent/SI3470397T1/sl unknown
- 2013-07-15 WO PCT/US2013/050539 patent/WO2014014835A2/en active Application Filing
- 2013-07-15 US US13/942,443 patent/US9115085B2/en active Active
- 2013-07-15 SG SG10201700873UA patent/SG10201700873UA/en unknown
- 2013-07-15 EP EP21212372.3A patent/EP4029854A1/en active Pending
- 2013-07-15 ES ES13740185.7T patent/ES2689430T3/es active Active
- 2013-07-15 ES ES18189607T patent/ES2905898T3/es active Active
- 2013-07-15 NZ NZ704662A patent/NZ704662A/en unknown
- 2013-07-15 HU HUE18189607A patent/HUE057925T2/hu unknown
- 2013-07-15 LT LTEP13740185.7T patent/LT2872488T/lt unknown
- 2013-07-15 LT LTEP18189607.7T patent/LT3470397T/lt unknown
- 2013-07-15 SG SG11201500236SA patent/SG11201500236SA/en unknown
- 2013-07-15 CN CN201380037479.XA patent/CN104684897A/zh active Pending
- 2013-07-15 EP EP13740185.7A patent/EP2872488B1/en not_active Revoked
- 2013-07-15 DK DK13740185.7T patent/DK2872488T3/en active
- 2013-07-15 RS RS20220121A patent/RS63122B1/sr unknown
- 2013-07-15 PT PT181896077T patent/PT3470397T/pt unknown
- 2013-07-15 DK DK18189607.7T patent/DK3470397T3/da active
- 2013-07-15 CN CN202111361393.5A patent/CN114409596A/zh active Pending
- 2013-07-15 RS RS20181268A patent/RS57795B1/sr unknown
- 2013-07-15 KR KR1020217034322A patent/KR20210130849A/ko not_active Ceased
- 2013-07-15 PT PT13740185T patent/PT2872488T/pt unknown
- 2013-07-15 KR KR1020207024326A patent/KR102318720B1/ko active Active
- 2013-07-15 SM SM20180565T patent/SMT201800565T1/it unknown
- 2013-07-15 SI SI201331143T patent/SI2872488T1/sl unknown
- 2013-07-15 CN CN201710546619.6A patent/CN107382860A/zh active Pending
- 2013-07-15 MY MYPI2015000129A patent/MY182428A/en unknown
- 2013-07-15 SG SG10202111314YA patent/SG10202111314YA/en unknown
- 2013-07-15 CN CN202210791828.8A patent/CN115093370A/zh active Pending
- 2013-07-15 PL PL18189607T patent/PL3470397T3/pl unknown
- 2013-07-15 HR HRP20220182TT patent/HRP20220182T1/hr unknown
- 2013-07-15 MX MX2015000504A patent/MX355428B/es active IP Right Grant
- 2013-07-15 EP EP18189607.7A patent/EP3470397B1/en active Active
- 2013-07-15 CA CA2879242A patent/CA2879242C/en active Active
- 2013-07-15 CN CN201710546191.5A patent/CN107501177B/zh active Active
- 2013-07-15 IN IN262KON2015 patent/IN2015KN00262A/en unknown
- 2013-07-15 CN CN201710546643.XA patent/CN107540607A/zh active Pending
2015
- 2015-01-11 IL IL236626A patent/IL236626B/en active IP Right Grant
- 2015-07-21 US US14/805,345 patent/US9617218B2/en active Active
2017
- 2017-03-17 US US15/462,688 patent/US10118897B2/en active Active
- 2017-10-20 JP JP2017203509A patent/JP2018009034A/ja active Pending
2018
- 2018-02-28 HK HK18102870.1A patent/HK1243409A1/zh unknown
- 2018-10-11 US US16/158,242 patent/US20190276408A1/en not_active Abandoned
- 2018-10-24 HR HRP20181751TT patent/HRP20181751T1/hr unknown
- 2018-10-31 CY CY181101128T patent/CY1120805T1/el unknown
2019
- 2019-12-16 US US16/716,433 patent/US20200115344A1/en not_active Abandoned
2022
- 2022-02-14 CY CY20221100127T patent/CY1125155T1/el unknown
- 2022-06-15 NO NO2022024C patent/NO2022024I1/no unknown
- 2022-06-15 FR FR22C1030C patent/FR22C1030I2/fr active Active
- 2022-06-20 LT LTPA2022510C patent/LTPA2022510I1/lt unknown

Also Published As

Publication number	Publication date
CN107382859B (zh)	2018-09-14
LT2872488T (lt)	2018-10-25
KR20150058154A (ko)	2015-05-28
CN109369524A (zh)	2019-02-22
HRP20220182T1 (hr)	2022-04-29
WO2014014835A3 (en)	2014-08-21
LTPA2022510I1 (pt)	2022-07-25
IL236626A0 (en)	2015-02-26
KR102318720B1 (ko)	2021-10-28
FR22C1030I1 (fr)	2022-09-09
MY182428A (en)	2021-01-25
US20200115344A1 (en)	2020-04-16
MX355428B (es)	2018-04-18
US20170190667A1 (en)	2017-07-06
EP3470397A1 (en)	2019-04-17
CN107382859A (zh)	2017-11-24
PT2872488T (pt)	2018-11-22
JP2018009034A (ja)	2018-01-18
EP2872488A2 (en)	2015-05-20
US9617218B2 (en)	2017-04-11
CA2879242A1 (en)	2014-01-23
KR20220164068A (ko)	2022-12-12
KR20210130849A (ko)	2021-11-01
MX2015000504A (es)	2015-07-17
SI3470397T1 (sl)	2022-07-29
SMT202200095T1 (it)	2022-03-21
AU2013290438A1 (en)	2015-02-19
SG11201500236SA (en)	2015-02-27
US10118897B2 (en)	2018-11-06
NZ704662A (en)	2017-07-28
CN107501177B (zh)	2018-12-07
AU2013290438B9 (en)	2018-07-19
DK2872488T3 (en)	2018-10-29
CN107501177A (zh)	2017-12-22
PL3470397T3 (pl)	2022-06-20
CN103539735B (zh)	2017-08-04
NO2022024I1 (no)	2022-06-15
KR20200102556A (ko)	2020-08-31
US20190276408A1 (en)	2019-09-12
AU2013290438C1 (en)	2019-01-03
BR112015001101A2 (pt)	2017-06-27
KR102149380B1 (ko)	2020-08-28
JP6491093B2 (ja)	2019-03-27
JP2015522616A (ja)	2015-08-06
PL2872488T3 (pl)	2019-01-31
CA2879242C (en)	2023-05-09
EP2872488B1 (en)	2018-08-22
HUE041458T2 (hu)	2019-05-28
US20140024676A1 (en)	2014-01-23
EP4029854A1 (en)	2022-07-20
CY1125155T1 (el)	2023-01-05
WO2014014835A8 (en)	2014-11-20
CN107540607A (zh)	2018-01-05
EP3470397B1 (en)	2021-12-29
US20150322015A1 (en)	2015-11-12
SG10202111314YA (en)	2021-12-30
AU2013290438B2 (en)	2017-09-14
ES2905898T3 (es)	2022-04-12
CN103539735A (zh)	2014-01-29
HK1243409A1 (zh)	2018-07-13
CN114409596A (zh)	2022-04-29
RS63122B1 (sr)	2022-05-31
SMT201800565T1 (it)	2018-11-09
IL236626B (en)	2020-03-31
HRP20181751T1 (hr)	2018-12-28
RS57795B1 (sr)	2018-12-31
SG10201700873UA (en)	2017-04-27
HUE057925T2 (hu)	2022-06-28
CY1120805T1 (el)	2019-12-11
ES2689430T3 (es)	2018-11-14
US9115085B2 (en)	2015-08-25
FR22C1030I2 (fr)	2024-08-02
WO2014014835A2 (en)	2014-01-23
PT3470397T (pt)	2022-02-18
CN104684897A (zh)	2015-06-03
CN115093370A (zh)	2022-09-23
LT3470397T (lt)	2022-02-25
DK3470397T3 (da)	2022-03-14
US20140303202A9 (en)	2014-10-09
SI2872488T1 (sl)	2018-11-30
CN107382860A (zh)	2017-11-24

Publication	Publication Date	Title
IN2015KN00262A (pt)	2015-06-12
PH12013501143A1 (en)	2013-07-08	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX2015000962A (es)	2015-04-16	COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS.
MX2021011906A (es)	2021-10-26	Composiciones de liberacion retardada de linaclotida.
MX2014010433A (es)	2015-04-13	Nueva forma cristalina de sulfato de sitagliptina.
CA2905610C (en)	2021-06-01	Hyaluronic acid derivatives
MX2013002948A (es)	2013-05-09	Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX2015009617A (es)	2016-04-20	Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
IN2014KN02722A (pt)	2015-05-08
MX347541B (es)	2017-04-28	Analogos de acido sialico.
WO2011107866A3 (en)	2011-12-29	Silyl-derivatives of polysaccharides
IN2015DN00085A (pt)	2015-05-29
MX2013013436A (es)	2013-12-06	Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2014004210A (es)	2014-05-28	Derivados de 2-oxo-piperidinilo.
MX367773B (es)	2019-09-05	Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
WO2014083575A3 (en)	2016-06-02	Improved process for the preparation of boceprevir intermediate
IN2013CH04314A (pt)	2015-08-28
WO2014076616A3 (en)	2014-07-10	Formulations of 5-azacytidine
WO2014122671A3 (en)	2014-12-24	Solid oral compositions of saxagliptin
MX351994B (es)	2017-11-06	Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2013046233A3 (en)	2013-06-13	Process for the preparation of octreotide acetate
IN2015DN02660A (pt)	2015-09-04
IN2014DN10683A (pt)	2015-08-28
WO2013064326A3 (de)	2014-05-22	Arjunolsäure zur erhöhung der sebumproduktion
TN2013000243A1 (en)	2014-11-10	Substituted 1-benzylcycloalkylcarboxlic acids and use thereof